Pulmocures
Pulmocures develops lung-targeted drug delivery technologies that concentrate therapeutic agents directly in pulmonary tissue, reducing systemic side effects. The company also creates adjustable medications tailored to individual patient characteristics and needs, with research programs addressing COVID-19 and other respiratory conditions.
- Healthcare Technology
- Biotechnology
- Drug Discovery & Therapeutics
Funding
Founders
Founder details are not available yet.
Product
Problem
Conventional respiratory medications often lack precision, delivering drugs systemically rather than directly to lung tissue, which reduces efficacy and increases the risk of side effects. Additionally, standard dosing protocols do not account for individual patient variability, limiting treatment effectiveness across diverse populations and respiratory conditions.
Solution
Pulmocures develops advanced lung-targeted drug delivery technologies designed to concentrate therapeutic agents precisely where they are needed most. The company creates adjustable medications that can be customized according to individual patient characteristics and clinical needs, improving treatment outcomes while minimizing systemic exposure. Their research pipeline includes therapies applicable to COVID-19, reflecting a commitment to addressing urgent respiratory health challenges. By combining proprietary drug targeting methods with continuous academic collaboration, Pulmocures aims to accelerate the transition of novel respiratory treatments from laboratory research to clinical application. The company's approach is guided by the principle of "bilimden insana" (from science to human), emphasizing a patient-centered development philosophy.
Target Audience
Primary customers are pharmaceutical companies and clinical research partners seeking advanced respiratory drug delivery technologies, as well as healthcare providers and patients requiring more effective, personalized treatments for lung conditions including COVID-19.
Features
- Proprietary lung-targeting drug delivery platform that concentrates therapeutic agents in pulmonary tissue
- Adjustable medication formulations that can be tailored to individual patient profiles and specific respiratory needs
- Research programs dedicated to developing treatments for COVID-19 and related viral respiratory infections
- Continuous integration of academic research findings to refine and update therapeutic approaches
- Specialized focus exclusively on pulmonary drug delivery, enabling deep expertise in respiratory therapeutics
- Actively tracks technological developments and builds proprietary technology in-house